Processing

Please wait...

Settings

Settings

Goto Application

1. EP0744892 - Anticoagulant compositions for platelets

Office European Patent Office
Application Number 95929639
Application Date 22.08.1995
Publication Number 0744892
Publication Date 04.12.1996
Publication Kind B1
IPC
A61B 5/15
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes; Identification of persons
15Devices for taking samples of blood
A61K 35/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
CPC
A61K 35/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
Applicants BAXTER INT
Inventors GRODE GERALD A
STEWART MARY A
Designated States
Priority Data 35781294 16.12.1994 US
9510705 22.08.1995 US
Title
(DE) Antikoagulierende Zusammensetzungen für Blutplättchen
(EN) Anticoagulant compositions for platelets
(FR) Compositions anticoagulantes pour plaquettes
Abstract
(EN)
A new citrate-based anticoagulant for donor whole blood provides good platelet yield and cell morphology at a significantly reduced risk of donor paresthesia during apheresis procedures. The primary citrate anticoagulant compositions include a citric acid to total citrate ration greater than about 30 %. The anticoagulants are mixed with whole blood to provide an anticoagulated blood mixture which contains a citric acid concentration of greater than about 5.0 mM, a total citrate concentration of less than about 20 mM, and an initial blood pH of less than about 6.75. The platelet rich products including PRP and PC prepared from blood collected in accordance with the invention exhibit better platelet yields and better platelet morphology on storage.

(FR)
Nouvel anti-coagulant à base de citrate pour le sang entier d'un donneur permet d'obtenir une bonne production des plaquettes ainsi qu'une bonne morphologie des cellules avec un risque considérablement réduit de parasthésie du donneur lors de procédures d'aphérèse. Les principales compositions anti-coagulantes à base de citrate ont un rapport acide citrique/quantité totale de citrate supérieur à environ 30 %. Les anti-coagulants sont mélangés à du sang entier afin d'obtenir un mélange de sang anti-coagulé dont la concentration en acide citrique est supérieure à environ 5,0 mM, une concentration totale de citrate inférieure à environ 20 mM, et un pH de sang initial inférieur à environ 6,75. Le produit riche en plaquettes y compris PRP et PC préparé à partir de sang récupéré selon l'invention présente de meilleurs taux de plaquettes et une meilleure morphologie des plaquettes pendant le stockage.